Amgen’s AMG510 combo exploration in colorectal cancer tumours poised for late 2019, early 2020
The theory behind combining AMG510 with a MEK inhibitor in CRC is that together they would target upstream and downstream KRAS events.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
